BioStacks

Supplement

Melatonin

Evidence

Strong

Reviewed May 2026

Evidence: 4 of 5 (Strong)

8 studies cited · 3 meta-analyses · 2 systematic reviews

What the evidence says

Melatonin is a hormone that regulates sleep-wake cycles. Supplemental melatonin is commonly used for sleep onset and jet lag. Generally well tolerated at typical doses; may cause grogginess in some people.

Multiple clinical trials confirm reduced sleep latency and jet lag symptoms at doses as low as 0.5mg

Top Melatonin supplements for…

Supports

SleepStrong

Top Melatonin supplements

4/5

Strong

8

RCTs reviewed

1

Null result

Take 0.3–1 mg, not 10 mg. Strong evidence for jet lag, delayed sleep-phase disorder, and modest sleep-onset reduction. Most retail gummies are 5–10x the effective dose — and bigger doses do not work better.

Never take melatonin during the day. Skip it if you take warfarin, immunosuppressants, or sleep medications without clinician input. Pediatric long-term safety is not established.

Research dossier

Clinical research on Melatonin

8 trials reviewed across 1 indication.

Strongest evidence

Sleep onset and circadian alignment

Strong

Mechanism

Melatonin binds MT1 and MT2 receptors in the suprachiasmatic nucleus, signaling the brain's master clock that biological night has begun. The effect is chronobiotic — it shifts and reinforces circadian timing — not sedative-hypnotic.

The honest dosing story: 0.3–1 mg taken 30–60 minutes before bed is as effective as 5 or 10 mg for sleep onset, and avoids the next-day grogginess and cortisol disruption that comes with mega-doses. Strongest indications are jet lag, delayed sleep-phase disorder, shift-work transitions, and pediatric autism-related insomnia.

Most useful for circadian-misalignment problems (jet lag, shift work, DSWPD). Less useful for sleep-maintenance insomnia and night-time anxiety. Healthy young adults with normal circadian rhythms typically gain very little.

Trials cited

  • Cochrane review — melatonin for jet lag

    positive · Systematic review

    Herxheimer & Petrie, 2002, Cochrane Database of Systematic Reviews

    Cochrane review of 10 randomized trials concluded melatonin taken close to local bedtime at the destination is remarkably effective at reducing jet lag after flights crossing five or more time zones, with strongest effect for eastward travel. The clearest indication for melatonin in the entire literature.

    Doses between 0.5 and 5 mg performed similarly. Larger doses were not more effective — they just produced more next-day grogginess.

  • Zhdanova — melatonin dose-response in older adults

    positive · RCT

    Zhdanova et al., 2001, Journal of Clinical Endocrinology & Metabolismn=30

    0.3 mg — a physiologic dose — restored sleep efficiency in poor sleepers and brought plasma melatonin into the normal nighttime range. The 3.0 mg dose also worked but produced hypothermia and pushed melatonin into morning hours, dragging next-day cortisol. Normal sleepers saw no benefit at any dose.

    Small (n=30) but the cleanest dose-response trial in the literature. The retail-gummy dose of 5–10 mg has no advantage over 0.3 mg and several disadvantages.

  • Ferracioli-Oda — melatonin for primary sleep disorders meta-analysis

    positive · Meta-analysis

    Ferracioli-Oda, Qawasmi, Bloch, 2013, PLoS ONEn=1683

    Pooled 19 RCTs, 1,683 subjects. Melatonin reduced sleep onset latency by 7.06 minutes, increased total sleep time by 8.25 minutes, and modestly improved sleep-quality scores (SMD 0.22). Real but modest — comparable to a strong cup of decaf, not to z-drugs.

    Effects are statistically reliable and clinically modest. People expecting transformative sleep effects from melatonin are usually disappointed.

  • Auld — primary sleep disorders systematic review

    positive · Systematic review

    Auld, Maschauer, Morrison, Skene, Riha, 2017, Sleep Medicine Reviews

    Systematic review of 12 RCTs from 5,030 screened citations. Strongest evidence for reducing sleep onset latency in primary insomnia and for entraining circadian rhythm in delayed sleep-phase syndrome and blind individuals. Modest evidence elsewhere.

    Heterogeneity of doses, formulations, and timing makes effect-size pooling imperfect. Authors call for larger trials with consistent protocols.

  • van Geijlswijk — melatonin for delayed sleep-phase disorder

    positive · Meta-analysis

    van Geijlswijk, Korzilius, Smits, 2010, Sleep

    Pooled meta-analysis confirmed melatonin advances sleep-wake rhythm in delayed sleep-phase disorder — moving the biological night earlier. Effect on sleep onset is consistent. The biggest variable is timing: take it 4–6 hours before current sleep onset, not at bedtime.

    Timing matters more than dose. Taking melatonin at the wrong circadian phase can shift the rhythm in the wrong direction.

  • Wade — prolonged-release melatonin (Circadin) in older insomnia

    positive · RCT

    Wade et al., 2007, Current Medical Research and Opinionn=354Industry-funded

    Older adults with primary insomnia on Circadin 2 mg showed significant improvements in self-rated sleep quality and next-morning alertness versus placebo over 3 weeks. The prolonged-release form is the basis for the EU prescription melatonin product approved for short-term insomnia in adults over 55.

    Older population only — the data does not extrapolate to younger adults. Manufacturer-funded.

  • Xiong — melatonin for sleep in children with autism

    positive · Meta-analysis

    Xiong et al., 2023, Neuropediatrics

    Meta-analysis confirmed shorter sleep onset latency, longer total sleep time, and fewer night wakings in children with ASD on melatonin. The evidence base in pediatric ASD insomnia is among the strongest pediatric melatonin indications.

    Pediatric long-term safety data is limited. Effects on puberty timing remain incompletely studied. Clinician supervision recommended for chronic pediatric use.

Honest-evidence ledger1 trial that didn’t move the needle

Surfacing failed trials alongside the positive evidence. Leaving them out would be marketing, not science.

  • Pediatric melatonin overdose surge

    negative · Observational

    Lelak et al., 2022, MMWR Morbidity and Mortality Weekly Report (CDC)n=260435

    CDC surveillance of US poison-control calls counted 260,435 pediatric melatonin ingestions between 2012 and 2021 — a 530% rise across the decade, with hospitalizations and deaths concentrated in unsupervised settings. Gummy formulations marketed like candy are the dominant driver.

    Not an efficacy trial — included as essential context. Retail melatonin is not a benign substance for kids in unrestricted access settings.

2 forms of Melatonin compared
  • Standard immediate-release melatonin

    Variable — oral bioavailability ranges 1–37%; sublingual is faster

    Best forSleep onset, jet lag, circadian shifting

    0.3–1 mg taken 30–60 minutes before target bedtime is the sweet spot. The Zhdanova 2001 dose-response trial is the cleanest evidence: 0.3 mg restored sleep efficiency in older poor sleepers; 3 mg did not work better and produced morning grogginess.

    sleep0.31 mg
  • Circadin (EU prescription, 2 mg)

    Prolonged-release melatonin

    Designed to mimic endogenous overnight melatonin curve

    Best forSleep maintenance and quality in adults over 55 with primary insomnia

    Two-mg Circadin tablets release across the night rather than as a bolus. The Wade 2007 RCT supports use in older adults; available by prescription in the EU and OTC in the US under various brands. Better choice than immediate-release if you wake at 2–3 AM.

    sleep22 mg
Side effects and drug interactions

Side effects

  • Next-morning grogginess

    Common · Common above 3 mg, rare below 1 mg

    The most common side effect at retail doses. Driven by melatonin still circulating into morning hours, suppressing cortisol awakening response. Disappears at 0.3–1 mg doses.

  • Vivid dreams or nightmares

    Uncommon

    Some users report unusually vivid or disturbing dreams, more pronounced at higher doses.

  • Headache

    Uncommon

    Mild headache occurs in roughly 5% of trial participants, typically resolving with dose reduction.

  • Daytime sleepiness

    Common

    Strongly dose-dependent. At retail doses (5–10 mg), residual sleepiness through the morning is common.

  • Impaired glucose tolerance

    Uncommon · Documented at 5 mg; effect worsens when dosed near meals

    Melatonin acutely blunts insulin secretion via MT2 receptors on pancreatic beta cells, raising post-meal glucose. The effect is largest when the dose overlaps with eating — a morning dose, or eating close to a nighttime dose, produces a markedly larger glucose spike than an evening dose on an empty stomach. Most relevant for people with prediabetes, diabetes, or the common MTNR1B risk variant. Practical takeaway: take melatonin at night, away from food.

  • Hormonal effects

    Rare

    Melatonin is a hormone. Long-term high-dose use may interact with reproductive hormone signaling. Pediatric long-term safety, particularly around puberty, is not fully established.

  • Pediatric overdose risk

    Severe

    US poison-control calls for pediatric melatonin ingestion rose 530% between 2012 and 2021. Gummy formulations marketed as candy are the dominant driver. Hospitalizations and deaths have occurred in unsupervised settings.

Drug interactions

  • Additive effect

    benzodiazepinesz-drugs (zolpidem, eszopiclone)sedating antihistaminesalcohol

    Additive sedation. Stacking melatonin with other CNS depressants amplifies daytime impairment.

    Combine only with clinician input. Do not drive if combining.

  • Additive effect

    warfarinanticoagulants

    Case reports describe altered INR on melatonin. The mechanism is not fully resolved.

    If you take warfarin, consult your prescriber and monitor INR closely after starting.

  • Reduces nutrient status

    fluvoxamineciprofloxacinestrogens

    These drugs inhibit CYP1A2, the enzyme that clears melatonin. The result is much higher and longer-lasting melatonin levels — and stronger next-day sedation.

    Use lower melatonin doses if combining, or skip melatonin while on these medications.

  • Other

    immunosuppressantscalcineurin inhibitors

    Melatonin has mild immunostimulatory effects.

    Avoid in transplant recipients and active autoimmune disease without specialist input.

  • Other

    antihypertensivesbeta-blockers

    Beta-blockers suppress endogenous melatonin and can create a deficiency state. Melatonin supplementation may help sleep on beta-blockers but can interact with blood-pressure control.

    Discuss with your prescriber if you are on beta-blockers and have new-onset insomnia.

Other critical caveats
  • Take 0.3–1 mg, not 10 mg. The Zhdanova 2001 dose-response data is unambiguous — bigger does not work better, it just lingers and disrupts your morning. Most retail gummies are 5–10x the effective dose.
  • Never take melatonin during the day. Daytime dosing shifts circadian rhythm in the wrong direction and produces next-day grogginess, not better sleep.
  • Do not give melatonin to children casually. Pediatric overdose calls are up 530% since 2012. Use only for diagnosed sleep disorders, with clinician input, and store as you would a medication — not on the kitchen counter.
  • If you take warfarin, immunosuppressants, fluvoxamine, or estrogens, talk to your prescriber before starting. Pharmacokinetic interactions can produce unexpectedly high melatonin levels.
  • Melatonin is a circadian timing tool, not a sedative. If you have sleep-maintenance insomnia (waking at 3 AM), a prolonged-release formulation or a different intervention is more likely to help than a standard melatonin gummy.
Frequently asked
  • How much melatonin should I take?
    0.3–1 mg, taken 30–60 minutes before target bedtime. The Zhdanova 2001 dose-response trial showed 0.3 mg restored sleep efficiency in older poor sleepers, and 3 mg did not work better — it just produced hypothermia and morning grogginess. Most US retail products contain 3, 5, or 10 mg, which is 5–30x the effective dose. Buy a 1 mg product or split a 3 mg tablet.
  • Why are gummies usually 5 or 10 mg if 0.3 mg is effective?
    Marketing. Bigger numbers signal stronger to consumers; the supplement industry exploits this. The clinical literature is clear that 0.3–1 mg matches or beats higher doses for sleep onset, with fewer side effects. Independent assays have also shown actual melatonin content often ranges from roughly 80% below to nearly 5x above the label, and one analysis of 31 products found about a quarter were also contaminated with serotonin — another reason precise dosing is harder than it looks, and USP-verified products are worth seeking out.
  • Will melatonin help my insomnia?
    It depends on what kind. Melatonin is a circadian timing signal, not a sedative-hypnotic. It works well for jet lag, shift-work transitions, delayed sleep-phase disorder (people who can't fall asleep until 3 AM), and some pediatric autism sleep problems. It works modestly for general primary insomnia — Cochrane-pooled effect is about 7 minutes of sleep-onset reduction. It does not work well for stress-driven middle-of-the-night waking.
  • Is melatonin safe long-term?
    For adults, short-term safety (up to a few months) is well-established at standard doses. Long-term safety (years) has not been studied rigorously. For children, the picture is murkier — pediatric chronic use, particularly through puberty, has unknown effects on hormone development. Default to the lowest effective dose, the shortest needed duration, and clinician oversight for pediatric chronic use.
  • Is melatonin addictive?
    No, in the chemical-dependence sense — there is no withdrawal syndrome, no dose escalation pattern, no compulsive use. Concerns about 'dependency' are usually psychological habituation: people feel they cannot sleep without it. Melatonin does not suppress endogenous production at standard doses, and stopping does not produce rebound insomnia.
  • Can I take melatonin every night?
    You can, but for most use cases you do not need to. For jet lag, take it for 3–5 nights at the destination. For DSWPD, use it as a circadian-shifting tool while you also fix sleep timing behaviorally. Nightly indefinite use is reasonable in older adults with primary insomnia at low dose, but is not necessary for most healthy adults.
  • What is Circadin and is it different?
    Circadin is a 2 mg prolonged-release melatonin tablet, prescription-only in the EU, OTC in the US under different names. It releases melatonin slowly across the night rather than as a bolus, mimicking the endogenous overnight curve. Better choice than immediate-release if you wake at 2–3 AM and cannot fall back asleep.

References

  1. 01NCCIH — Melatonin: What You Need To Know
  2. 02AASM Clinical Practice Guideline — Pharmacologic Treatment of Chronic Insomnia
  3. 03Erland & Saxena 2017 — Melatonin supplements: serotonin contamination and label variability (J Clin Sleep Med)

Last reviewed2026-05-07